This educational webinar is aimed at healthcare professionals and has been organised and funded by BioCryst Pharmaceuticals.
Dear ,
This webinar, hosted by Hannah Moir, EMJ, London, UK, features renowned allergy and clinical immunology expert, Sorena Kiani, Consultant Immunologist at the Royal Free Hospital, London, UK.
Kiani presents a comprehensive overview of the different angioedema subtypes, pathophysiology of bradykinin-mediated angioedema, and available treatment options for hereditary angioedema (HAE). He also delivers real-world insights on berotralstat▼, the first oral prophylactic treatment for HAE, highlighting efficacy and safety data for its use in patients aged ≥12 years.
The pair also discuss the impact of HAE aetiology on therapeutic decision-making, criteria for use of oral prophylaxis in HAE management, treatment considerations for patients, considerations for specific situations, and follow-up strategies for those who receive this therapy.
Watch the full webinar for deeper insights.
Biographies
Sorena Kiani
Sorena Kiani is a consultant immunologist at the Royal Free Hospital, London, UK, with expertise in allergy and clinical immunology. He earned his medical degree and PhD in immunology from University College London, UK, and specialised in clinical immunology at King’s College Hospital, London, UK. Kiani was recognised by the European Academy of Allergy and Clinical Immunology (EAACI) in 2010, for developing an innovative desensitisation method for anaphylaxis-causing proteins.
Prescribing information for BioCryst products mentioned in this article: Ordaleyo (berotralstat) can be found here - link. Always consult local prescribing information in country of practice as information may vary.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: https://link.edgepilot.com/s/c2656bad/I0-Y_lXF1EWURaSipyXxtw?u=http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. For non-UK HCPs, suspected adverse reactions should be reported via national reporting system in country of practice.
